Mark Genovese Joins Gilead to Lead Clinical Development of Company’s Inflammation Programs
June 01 2020 - 4:05PM
Business Wire
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Mark
Genovese, MD, has been appointed Senior Vice President,
Inflammation, with responsibility for overseeing the clinical
development of the company’s investigational portfolio of
treatments for inflammatory conditions.
Dr. Genovese, who has already begun his new role, comes to the
company from Stanford University, where he was on the faculty for
more than 21 years and most recently served as the James W. Raitt
Professor of Medicine and Clinical Chief in the Division of
Immunology and Rheumatology. At Stanford, he established a clinical
research program focused on translational medicine in autoimmune
diseases and led numerous investigator-initiated studies and
international multi-center trials for the treatment of
rheumatological diseases, including arthritis. He received his
undergraduate degree from the University of Notre Dame and his
medical degree from the Johns Hopkins University School of
Medicine. Dr. Genovese will report to Merdad Parsey, MD, PhD, Chief
Medical Officer.
Gilead is expanding its work in the field of inflammatory
diseases, with the goal of advancing new products for patients in
an area where, despite having approved therapies, significant need
for new treatment remains. Gilead has filed for regulatory approval
in the United States, Europe and Japan of a potential treatment for
rheumatoid arthritis (RA), which, if approved, would be the
company’s first medicine to treat an inflammatory disease. Gilead
is focused on expanding its work across a broad range of
inflammatory conditions with the goal of helping physicians and
people with inflammatory diseases reach their treatment goals. Dr.
Genovese will also have responsibility for the company’s fibrosis
clinical research programs including nonalcoholic steatohepatitis,
idiopathic pulmonary fibrosis and systemic sclerosis.
“We are very pleased to welcome Mark to Gilead – he is one of
the leading researchers and clinicians in the fields of immunology
and rheumatology, and we will benefit tremendously from his
expertise as we seek to bring forward new treatments that improve
care for patients with rheumatoid arthritis, inflammatory bowel
disease and other debilitating conditions,” said Dr. Parsey. “The
company has set the ambitious goal of introducing 10 transformative
medicines over the next decade and I believe that Mark’s
appointment will help us significantly advance our work in
inflammation.”
“Gilead has a long history of transforming care for people with
serious illnesses, such as HIV and viral hepatitis, and I’ve
watched as the company has worked over the past several years to
add programs, resources and individuals to bring that same
scientific rigor and innovation to patients with inflammatory
diseases, where doctors and patients are so much in need of better
treatment options,” commented Dr. Genovese. “In my prior academic
role, I had the opportunity to work with Gilead as the company
began to grow its work in inflammatory diseases, and I’m excited to
join the talented team. I look forward to the progress we will make
together to transform care for patients.”
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical
company that discovers, develops and commercializes innovative
medicines in areas of unmet medical need. The company strives to
transform and simplify care for people with life-threatening
illnesses around the world. Gilead has operations in more than 35
countries worldwide, with headquarters in Foster City,
California.
For more information about Gilead, please visit
the company’s website at www.gilead.com, follow Gilead on Twitter
(@Gilead Sciences) or call Gilead Public Affairs at 1-800-GILEAD-5
or 1-650-574-3000.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200601005635/en/
Doug Maffei, PhD, Investors (650) 522-2739
Marni Kottle, Media (650) 522-5388
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Sep 2023 to Sep 2024